Product image of Lantus Solostar (Insulin Glargine) supplied by GNH India

Lantus Solostar

Active Ingredient:
Insulin Glargine
Origin:
EU

Lantus Solostar (Insulin Glargine)

Insulin glargine, the active ingredient in Lantus Solostar, is a long‑acting insulin analog presented as a solution for subcutaneous use. It provides basal insulin coverage to help manage blood glucose levels in individuals with diabetes mellitus, including both type 1 and type 2 disease.

GNH India supplies Lantus Solostar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and offers reliable global distribution. Clients benefit from consistent product availability and regulatory compliance across markets.

Manufacturer / TM Owner

Sanofi-Aventis Deutschland Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lantus Solostar, a long‑acting insulin analog, is used to control hyperglycemia in diabetes mellitus.

  • Type 1 diabetes mellitus: provides basal insulin to maintain stable fasting glucose and reduce glycemic excursions.
  • Type 2 diabetes mellitus: adds basal insulin when oral agents are insufficient to achieve target glucose levels.
  • Insulin deficiency (basal insulin requirement): supplies steady insulin levels to lower fasting blood glucose and support overall glycemic control.

How It Works

  • Insulin glargine binds to insulin receptors on peripheral tissues, activating the receptor tyrosine kinase pathway. This promotes translocation of GLUT‑4 transporters, enhancing glucose uptake into muscle and adipose tissue while suppressing hepatic gluconeogenesis. The analog forms microprecipitates after subcutaneous injection, resulting in a prolonged, peak‑less release that maintains basal insulin concentrations for up to 24 hours.

Side Effects

Common Side Effects

  • Hypoglycemia: low blood glucose episodes, especially if dosing is excessive.
  • Injection site reactions: redness, swelling, or itching at the injection site.
  • Weight gain: gradual increase associated with improved glucose utilization.
  • Lipodystrophy: localized changes in fat tissue at injection sites.
  • Edema: mild fluid retention, often peripheral.

Serious or Rare Side Effects

  • Severe hypoglycemia: neurological impairment requiring immediate assistance.
  • Allergic reactions: rash, urticaria, or angioedema.
  • Anaphylaxis: rare, potentially life‑threatening systemic reaction.
  • Insulin antibody formation: may alter insulin efficacy.
  • Ketoacidosis: rare if insulin effect is insufficient.

Precautions & Warnings

Lantus Solostar requires careful monitoring and patient education.

  • Blood glucose monitoring: check levels regularly to adjust dose as needed.
  • Dose adjustments during illness: may need temporary increase to maintain control.
  • Alcohol consumption: can mask hypoglycemia symptoms; use with caution.
  • Renal impairment: reduced clearance may increase hypoglycemia risk.
  • Hypoglycemia awareness: educate patients on recognizing early signs.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Lantus Solostar may interact with several medications affecting glucose homeostasis.

Major Interactions (Avoid)

  • Concurrent use with other rapid‑acting insulins: heightened risk of severe hypoglycemia.
  • Combination with meglitinides: additive glucose‑lowering effect can precipitate hypoglycemia.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may mask typical hypoglycemia symptoms such as tachycardia.
  • ACE inhibitors: can potentiate insulin’s glucose‑lowering action.
  • Oral contraceptives: may slightly alter insulin sensitivity and glucose tolerance.
  • Corticosteroids: can increase blood glucose, requiring dose reassessment.

Frequently Asked Questions

Lantus Solostar contains insulin glargine, a long‑acting insulin analog used to provide basal insulin coverage for people with type 1 or type 2 diabetes mellitus, helping to maintain stable blood glucose levels throughout the day.

Insulin glargine binds to insulin receptors, activating cellular pathways that increase glucose uptake into muscle and fat cells and suppress liver glucose production. Its formulation creates a slow, steady release after subcutaneous injection, delivering a peak‑less basal insulin effect for up to 24 hours.

The dose of Lantus Solostar is individualized. A qualified prescriber determines the appropriate amount based on the patient’s age, weight, type of diabetes, current glucose control, and other medications. Patients should follow the prescribing clinician’s instructions precisely.

Insulin glargine is classified as a pregnancy‑category B drug in many regions, indicating no proven risk in animal studies, but human data are limited. It may be used when the benefits outweigh potential risks. Breastfeeding mothers should consult their healthcare provider, as insulin is minimally transferred into breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and import documentation.

Lantus Solostar (insulin glargine) offers a 24‑hour, peak‑less profile similar to other long‑acting analogs such as insulin detemir or degludec. Compared with older NPH insulin, glargine provides more consistent basal coverage with a lower risk of nocturnal hypoglycemia, but individual response and cost considerations may influence choice.

Lantus Solostar should be stored in a refrigerator at 2‑8 °C, protected from light. Do not freeze or shake the vial. Once in use, the product may be kept at controlled room temperature (up to 30 °C) for a maximum of 28 days, as indicated on the label.

Lantus Solostar is administered by subcutaneous injection, typically once daily at the same time each day. Injection sites include the abdomen, thigh, or upper arm, rotating sites to reduce lipodystrophy. Patients should be trained on proper injection technique and needle disposal.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated to recognize early hypoglycemia signs and have a rapid‑acting carbohydrate source readily available.

Lantus Solostar is contraindicated in individuals with a known hypersensitivity to insulin glargine or any of its excipients. It should also be avoided in patients with severe hypoglycemia unawareness unless closely monitored, and in those for whom a rapid‑acting insulin regimen is more appropriate.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Insulin Glargine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT